Sarepta Therapeutics, Inc. annual report, FY2023

Sarepta Therapeutics, Inc. — Form 10-K Summary

Reporting period: Fiscal year ended December 31, 2023. The filing is an annual report and does not provide a standalone fourth-quarter income statement. Sarepta is a commercial-stage rare-disease biopharmaceutical company focused on RNA-targeted therapeutics, gene therapy and other genetic medicines, primarily for Duchenne muscular dystrophy.

Business Context

Commercial products are EXONDYS 51, VYONDYS 53, AMONDYS 45 and ELEVIDYS. All four received accelerated FDA approval.
ELEVIDYS, launched in the second quarter of 2023, is the company’s first commercial gene therapy and is approved for ambulatory pediatric Duchenne patients aged 4 through 5 years, subject to a stated exon 8/9 contraindication.
The pipeline includes more than 40 programs, including SRP-5051, a PPMO Duchenne program, and SRP-9003, a gene therapy program for limb-girdle muscular dystrophy.
As of December 31, 2023, Sarepta had 1,314 employees, including 877 engaged in research and development.

2023 Financial Metrics

Metric	2023	2022	Change
Total revenue	$1,243.3 million	$933.0 million	+33%
Product revenue	$1,144.9 million	$843.8 million	+36%
Collaboration and other revenue	$98.5 million	$89.2 million	+10%
Operating loss	$267.8 million	$536.2 million	Improved by $268.4 million
Net loss	$536.0 million	$703.5 million	Improved by $167.5 million
Net loss per share	$5.80	$8.03	Improved by $2.23
Cash used in operating activities	$501.0 million	$325.3 million	Use increased by $175.6 million

Product revenue by product: EXONDYS 51 $540.6 million, AMONDYS 45 $273.8 million, ELEVIDYS $200.4 million and VYONDYS 53 $130.2 million.
U.S. product revenue was $998.3 million, including $797.9 million from PMO products and $200.4 million from ELEVIDYS. PMO product revenue outside the U.S. was $146.6 million.
Cost of sales, including amortization of in-licensed rights, was approximately $151.9 million. Implied gross profit was approximately $1,091.4 million and implied gross margin was approximately 87.8%.
Research and development expense was $877.4 million, essentially flat year over year. Selling, general and administrative expense increased 7% to $481.9 million.
Implied operating margin was approximately negative 21.5%; implied net margin was approximately negative 43.1%.
Stock-based compensation was $182.5 million, and strategic investment impairment expense was $30.3 million.

Liquidity, Debt and Cash Flow

Cash, cash equivalents, short-term investments and restricted cash totaled $1.692 billion at year-end, comprising $428.4 million of cash and equivalents, $1.248 billion of short-term investments and $15.6 million of restricted cash.
Total borrowings were $1.238 billion at carrying value, down from $1.544 billion in 2022. The balance comprised approximately $105.8 million of 1.50% convertible notes due in 2024 and $1.150 billion of 1.25% convertible notes due in 2027.
In March 2023, Sarepta exchanged $313.5 million of 2024 Notes for approximately 4.5 million common shares and recorded a $387.3 million loss on debt extinguishment. The remaining 2024 Notes mature in 2024.
Working capital was $1.926 billion at December 31, 2023, compared with $1.938 billion at December 31, 2022.
Operating cash use increased primarily because of the net loss, a $185.7 million increase in accounts receivable, a $147.7 million increase in inventory, and an $86.8 million decrease in deferred revenue.
Investing cash use was $165.8 million, while financing activities provided $125.0 million. The company stated that available liquidity is sufficient to fund its current operating plan for at least the next 12 months.

Material Changes Versus 2022

Revenue growth was driven by the launch of ELEVIDYS and higher demand for all three PMO products. ELEVIDYS contributed $200.4 million of 2023 revenue despite launching in the second quarter.
Operating loss narrowed substantially because revenue growth outpaced the increase in total operating expenses.
Net loss improvement was partly offset by the $387.3 million debt-extinguishment loss, compared with $125.4 million in 2022.
R&D spending shifted toward clinical trials and personnel, while manufacturing expense declined due partly to capitalization of commercial ELEVIDYS inventory after approval and the absence of certain 2022 Thermo minimum-purchase costs.
SG&A increased due primarily to ELEVIDYS launch activities, higher professional services and personnel costs, partially offset by lower stock-based compensation associated with the prior CEO award modification.
The company sold the ELEVIDYS Priority Review Voucher for $102.0 million in June 2023, recognizing the amount as a gain.
Inventory increased to $514.2 million from $366.5 million, while accounts receivable increased to $400.3 million from $214.6 million.

Outlook, Guidance and Key Risks

The filing does not provide quantitative 2024 revenue, earnings or cash-flow guidance.
The FDA granted priority review to Sarepta’s ELEVIDYS efficacy supplement seeking removal of age and ambulatory restrictions; the stated review goal date was June 21, 2024. Sarepta also submitted the Phase 3 confirmatory study package seeking conversion from accelerated to traditional approval.
Management expected to meet with the FDA regarding SRP-5051 in the second half of 2024. The filing notes a prior clinical hold related to hypomagnesemia, which was lifted in August 2022.
Study SRP-9003-301, a Phase 3 multinational open-label study, began screening in January 2024.
All four products remain subject to post-marketing requirements associated with accelerated approval. Failure to verify clinical benefit, adverse safety findings or delays in required studies could lead to labeling changes, restrictions or withdrawal of approval.
ELEVIDYS may compete with the PMO products in overlapping patient populations, potentially reducing PMO sales and creating inventory write-off risk.
Sarepta relies on third-party manufacturers, including Thermo Fisher, Catalent and Aldevron. Manufacturing capacity, cGMP compliance, supply interruptions and demand forecasting remain material risks.
Payor coverage, prior authorization, reimbursement levels and evolving healthcare-price controls could materially affect product adoption and revenue, particularly for high-cost gene therapy.
Material contractual obligations included $1.440 billion of manufacturing commitments, $362.4 million of lease obligations and $1.315 billion of debt obligations, including interest. The company also disclosed up to $3.2 billion of contingent development, regulatory, commercial and royalty-related payments under collaboration and license agreements.
Patent litigation remains significant, including proceedings involving Regenxbio and the University of Pennsylvania concerning ELEVIDYS manufacturing technology, and litigation with Nippon Shinyaku concerning exon 53 skipping patents and VYONDYS 53. The filing states that no material litigation accrual was recorded and no material loss range was estimable as of December 31, 2023.
Management reported no material cybersecurity incidents as of the filing date and concluded that disclosure controls and internal control over financial reporting were effective.

Important Facts for Investors to Verify

FDA decisions and confirmatory data supporting potential traditional approval and label expansion for ELEVIDYS.
ELEVIDYS demand, payer coverage, manufacturing yields, gross margin and any cannibalization of EXONDYS 51, AMONDYS 45 or VYONDYS 53.
Cash burn, the ability to fund operations beyond the stated 12-month horizon and repayment or refinancing of the 2024 Notes.
Progress, safety and regulatory direction for SRP-5051 and SRP-9003, including any additional clinical holds or adverse events.
Resolution and potential financial impact of the Regenxbio/U-Penn and Nippon Shinyaku patent proceedings.
Inventory utilization and potential write-offs, particularly as gene therapy adoption changes demand for PMO products.
Actual manufacturing commitments, supply capacity and dependence on Catalent, Thermo Fisher, Aldevron and other contract manufacturers.